{'fraction_non_alphanumeric': 0.0313588850174216, 'fraction_numerical': 0.018118466898954706, 'mean_word_length': 5.410714285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacoeconomics of cisplatin-based chemoradiation in cervical cancer: a review

Is the use of cisplatin-based chemoradiation therapy, which has become the new standard of care for locally-advanced cervical cancer, cost-effective? To evaluate this, a pharmacoeconomic analysis of five recent Phase III trials of cisplatin-based chemoradiation for the treatment of locally-advanced cervical cancer was conducted. Using an economic model, we applied cost data to resource-use data derived from the cisplatin-based chemoradiation arms of these randomised trials. We examined the cisplatin-based chemoradiation benefits in terms of increased median survival time. Incremental costs were divided by the difference in survival to determine the cost per patient benefited. Cost per life-year gained were calculated based on both published survival and estimated survival. Costs of cisplatin-based chemoradiation therapy regimens per life-year gained varied from US$2709 – 27,882 based on published survival and US$350 – 2860 based on estimated survival. Variations in regimen cost were largely dependent on in-patient or out-patient administration costs. Costs for cisplatin and 5-flourouracil were US$10,037 per in-patient compared to US$3431 for out-patient treatment. In conclusion, cisplatin-based chemoradiation regimens increased mean survival at an acceptable cost per life-year gained in both the in-patient and out-patient settings.